
GREYLEDGE TECHNOLOGIES INC
OperatingGreyledge Technologies, Inc.
Healthcare · Lone Tree, CO · Founded 2020
Regenerative medicine, stem cell therapies & ai precision data analytics
Financials
FY2022–FY2023 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Valuation caps on SAFE / convertible note roundsDashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth.
Fundraising history
Team
10 people
Dr. Karli is a Harvard trained physician and Regenerative Medicine thought leader. He’s lectured and published extensively in the field and has been featured in high level media publications like the Wall Street Journal, NY Times and ESPN Magazine. He founded and guided the company from inception in 2010 through extensive growth and development.

Jim is a Navy veteran, HBS Grad and former VP investment banker at Goldman Sachs in M&A and Financial Sponsor Coverage. He joined Nexphase Capital Partners in 2008 where he ran the Industrials Group as a Partner. In 2018, he founded Emerald Lake Advisors in order to focus on investing and advising small entrepreneurial companies.

Zoe is a Univ of Virginia graduate and Navy veteran, with business experience in seasoned and start-up companies. She has expertise in sales, e-comm, distribution and operations. She held leadership roles in pharma sales with Novartis, medical device sales with Depuy Spine, and in conjunction co-developed a successful private distributorship.

Connor graduated from the Univ of Colorado. He worked at IBM in various engineering and management roles then joined Greyledge in 2022. He built the Greyledge Data Cloud, which incorporated AI to sift and sort biologic response trends while working to create predictive models for varying treatments. It’s the first-of-its-kind stem cell data system.

Mark is an Army veteran. He held varying director and leadership roles both nationally and internationally for Celerity, Inc. and Celling Biosciences collectively from 1999-2017. He joined Greyledge in 2017 and is instrumental in managing logistics, supply chain and facility implementations across the US and EU.

Ademir Karisik is a global digital executive at Amentum with extensive experience in information and operational technology. He specializes in strategic planning, partnership management, and team building, supporting clients and teams across six continents. A proven leader in operational technology cyber resiliency, Ademir drives process improvements, enhances workflows, and implements global go-to-market strategies. His expertise in fostering international teams and delivering innovative solutions aligns with Greyledge Tech's mission to lead in innovation and excellence. Ademir holds credentials including CFE, MBA, and TS/SCI, reflecting his dedication to digital transformation and leadership.
Show 1 more personShow fewer

Dr. Michael Coleman has more than 29 years of experience as a research scientist and executive in the biotechnology industry. He has been continuously involved in the development and commercialization of regenerative medicine products in the USA and EU since 2006.
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 0 of 2 annual reports (FY2024–FY2025)
Missing: 2024, 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.